Generic drug maker Impax Laboratories Inc. is challenging patents underpinning the blockbuster Purdue Pharma LP painkiller OxyContin.
Hayward-based Impax (NASDAQ: IPXL) said Monday that it filed an abbreviated new drug application, or ANDA, for a generic version of OxyContin in various controlled-release tablet doses. It sought so-called “Paragraph IV” certification, which claims that its drug does not infringe on patents or that those patents are unenforceable.
Stamford, Conn.-based Purdue, as well as Rhodes Technologies the University of Texas system’s board of regents and Grunenthal GbmH, filed suit Friday in the U.S. District Court for Southern New York, claiming that Impax’s generic oxycodone hydrochloride infringes on patents.
No comments:
Post a Comment